Piper Jaffray analyst Joshua Schimmer says 2016 isn't starting out as a banner year for biotechs after larger names in the space yesterday offered "fairly lackluster" guidance outlooks. He calls Vanda (VNDA) and Ignyta (RXDX) "bright spots" following the companies' conference presentations. bluebird bio (BLUE) sold off after its presentation slides indicated little update for LentiGlobin until later in the year, Schimmer tells investors in a research note. The company "continues to search for its communications footing," he writes. Regarding BioMarin (BMRN), Schimmer says it's hard to know if reveglucosidase for Pompe's improves on the profile of Lumizyme.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Intra-Cellular Therapies... To see the rest of the story go to thefly.com. See Story Here